{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:12:51Z","timestamp":1761948771365,"version":"3.41.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>We investigated differences in quality of life (QoL) in patients enrolled on a phase I\/II dose-escalation study of 3-fraction resection cavity stereotactic radiosurgery (SRS) for large brain metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Eligible patients had 1 to 4 brain metastases, one of which was a resection cavity 4.2 to 33.5\u2009cm<jats:sup>3<\/jats:sup>. European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaires core-30 (QLQ-30) and brain cancer specific module (QLQ-BN20) were obtained before SRS and at each follow-up. Nine scales were analyzed (global health status; physical, social, and emotional functioning; motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty). QoL was assessed with mixed effects models. Differences \u226510 points with <jats:italic toggle=\"yes\">q<\/jats:italic>-value (adjusted <jats:italic toggle=\"yes\">P<\/jats:italic>-value to account for multiplicity of testing) &lt;0.10 were considered significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Between 2009 and 2014, 50 enrolled patients completed 277 QoL questionnaires. Median questionnaire follow-up was 11.8 months. After SRS, insomnia demonstrated significant improvement (<jats:italic toggle=\"yes\">q<\/jats:italic>=0.032, \u221217.7 points at 15\u2009mo post-SRS), and future uncertainty demonstrated significant worsening (<jats:italic toggle=\"yes\">q<\/jats:italic>=0.018, +9.9 points at 15\u2009mo post-SRS). Following intracranial progression and salvage SRS, there were no significant QoL changes. The impact of salvage whole brain radiotherapy could not be assessed because of limited data (n=4 patients). In the 28% of patients that had adverse radiation effect, QoL had significant worsening in 3 metrics (physical functioning, <jats:italic toggle=\"yes\">q<\/jats:italic>=0.024, emotional functioning <jats:italic toggle=\"yes\">q<\/jats:italic>=0.001, and future uncertainty, <jats:italic toggle=\"yes\">q<\/jats:italic>=0.004).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>For patients treated with 3-fraction SRS for large brain metastasis cavities, 8 of 9 QoL metrics were unchanged or improved after initial SRS. Intracranial tumor progression and salvage SRS did not impact QoL. Adverse radiation effect may be associated with at least short-term QoL impairments, but requires further investigation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000868","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T23:34:00Z","timestamp":1632526440000},"page":"588-595","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Phase I\/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases"],"prefix":"10.1097","volume":"44","author":[{"given":"Elham","family":"Rahimy","sequence":"first","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A.","family":"Dudley","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Johns Hopkins University, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"von Eyben","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erqi L.","family":"Pollom","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kira","family":"Seiger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Modlin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Wynne","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylann","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"University of California, Irvine, School of Medicine, Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa R.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, Los Angeles"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Chang","sequence":"additional","affiliation":[{"name":"Neurosurgery, Stanford University, Stanford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris C.","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Hancock","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Adler","sequence":"additional","affiliation":[{"name":"Neurosurgery, Stanford University, Stanford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Li","sequence":"additional","affiliation":[{"name":"Neurosurgery, Stanford University, Stanford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara Y.H.","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Santa Clara Valley Medical Center, San Jose, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott G.","family":"Soltys","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0305-7372(03)00105-1","article-title":"The management of brain metastases","volume":"29","author":"Patchell","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ijrobp.2018.10.038","article-title":"Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24 trials","volume":"103","author":"Lehrer","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ijrobp.2013.03.037","article-title":"Multidose stereotactic radiosurgery (9 Gy \u00d7 3) of the postoperative resection cavity for treatment of large brain metastases","volume":"86","author":"Minniti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multifraction (3 \u00d7 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis","volume":"95","author":"Minniti","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"author":"Soltys","key":"R10-20250527"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3747\/co.v15i5.290","article-title":"Quality of life in brain metastases radiation trials: a literature review","volume":"15","author":"Wong","year":"2008","journal-title":"Curr Oncol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/NCC.0b013e318269040f","article-title":"Comparison between patient-reported and clinician-observed symptoms in oncology","volume":"36","author":"Xiao","year":"2013","journal-title":"Cancer Nurs"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/jamaoto.2016.0656","article-title":"Comparison of patient- and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer","volume":"142","author":"Falchook","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00435979","article-title":"The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires","volume":"5","author":"Osoba","year":"1996","journal-title":"Qual Life Res"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","article-title":"An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients","volume":"46","author":"Taphoorn","year":"2010","journal-title":"Eur J Cancer"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijrobp.2007.06.068","article-title":"Stereotactic radiosurgery of the postoperative resection cavity for brain metastases","volume":"70","author":"Soltys","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ijrobp.2019.11.022","article-title":"Stereotactic radiosurgery for resected brain metastases: single-institutional experience of over 500 cavities","volume":"106","author":"Shi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.ijrobp.2011.09.025","article-title":"Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL","volume":"83","author":"Caissie","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijrobp.2017.01.242","article-title":"Phase 1\/2 trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent and adjuvant temozolomide in newly diagnosed supratentorial glioblastoma: health-related quality of life results","volume":"98","author":"Pollom","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1471-2407-12-283","article-title":"Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases","volume":"12","author":"Steinmann","year":"2012","journal-title":"BMC Cancer"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijrobp.2013.02.013","article-title":"Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide","volume":"86","author":"Minniti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12094-017-1703-5","article-title":"Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial","volume":"20","author":"Kepka","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00066-019-01506-w","article-title":"Quality of life in patients with limited (1-3) brain metastases undergoing stereotactic or whole brain radiotherapy: a prospective study of the DEGRO QoL working group","volume":"196","author":"Steinmann","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13566-012-0044-9","article-title":"Content validation of the EORTC QLQ-BN20+2 with patients and health care professionals to assess quality of life in brain metastases","volume":"1","author":"Nguyen","year":"2012","journal-title":"J Radiat Oncol"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.2011.41.0639","article-title":"A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results","volume":"31","author":"Soffietti","year":"2013","journal-title":"J Clin Oncol"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12874-016-0144-0","article-title":"Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data","volume":"16","author":"Ashbeck","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2288-14-118","article-title":"Handling missing data in RCTs; a review of the top medical journals","volume":"14","author":"Bell","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12885-016-2152-1","article-title":"Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review","volume":"16","author":"Fiteni","year":"2016","journal-title":"BMC Cancer"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdq726","article-title":"Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients","volume":"22","author":"Maringwa","year":"2011","journal-title":"Ann Oncol"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12955-020-01344-w","article-title":"How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods","volume":"18","author":"Mouelhi","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.21037\/jtd.2017.05.34","article-title":"A general introduction to adjustment for multiple comparisons","volume":"9","author":"Chen","year":"2017","journal-title":"J Thorac Dis"},{"key":"R39-20250527","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/028418600750013384","article-title":"Health-related quality of life measured by the EORTC QLQ-C30\u2014reference values from a large sample of Swedish population","volume":"39","author":"Michelson","year":"2000","journal-title":"Acta Oncol"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2016.10.005","article-title":"Stereotactic radiotherapy of the tumor bed compared to whole brain radiotherapy after surgery of single brain metastasis: results from a randomized trial","volume":"121","author":"K\u0119pka","year":"2016","journal-title":"Radiother Oncol"},{"key":"R41-20250527","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III Trial NRG Oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"R42-20250527","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2013.02.033","article-title":"Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214","volume":"86","author":"Gondi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R43-20250527","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","article-title":"Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase III, non-inferiority, randomised trial","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"key":"R45-20250527","first-page":"214","article-title":"Quality of reporting and assessment of patient-reported health-related quality of life in patients with brain metastases: a systematic review","volume":"5","author":"DiRisio","year":"2018","journal-title":"Neurooncol Pract"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:07:12Z","timestamp":1748365632000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000868"}},"subtitle":["Health-related Quality of Life Outcomes"],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000868","relation":{},"ISSN":["0277-3732"],"issn-type":[{"type":"print","value":"0277-3732"}],"subject":[],"published":{"date-parts":[[2021,9,22]]}}}